254 related articles for article (PubMed ID: 18839053)
1. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
Nar A; Gedik O
Acta Diabetol; 2009 Jun; 46(2):113-8. PubMed ID: 18839053
[TBL] [Abstract][Full Text] [Related]
2. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
[TBL] [Abstract][Full Text] [Related]
3. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Panahi Y; Ghamarchehreh ME; Beiraghdar F; Zare R; Jalalian HR; Sahebkar A
Hepatogastroenterology; 2012 Oct; 59(119):2099-2103. PubMed ID: 23234816
[TBL] [Abstract][Full Text] [Related]
6. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
[TBL] [Abstract][Full Text] [Related]
7. The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
Li S; Li H; Wang R; Zhang JP
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(15):3490-3495. PubMed ID: 28829491
[TBL] [Abstract][Full Text] [Related]
8. Metformin ameliorates treatment of obese type 2 diabetic patients with mental retardation; its effects on eating behavior and serum leptin levels.
Komori T; Yoshida F; Nakamura J; Miyazaki S; Miura H; Iguchi A
Exp Clin Endocrinol Diabetes; 2004 Sep; 112(8):422-8. PubMed ID: 15372361
[TBL] [Abstract][Full Text] [Related]
9. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
10. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
Wang X; Zhao B; Sun H; You H; Qu S
Front Endocrinol (Lausanne); 2022; 13():866189. PubMed ID: 36072931
[TBL] [Abstract][Full Text] [Related]
11. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.
Putz DM; Goldner WS; Bar RS; Haynes WG; Sivitz WI
Metabolism; 2004 Nov; 53(11):1454-61. PubMed ID: 15536601
[TBL] [Abstract][Full Text] [Related]
13. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
14. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
Nadeau KJ; Ehlers LB; Zeitler PS; Love-Osborne K
Pediatr Diabetes; 2009 Feb; 10(1):5-13. PubMed ID: 18721166
[TBL] [Abstract][Full Text] [Related]
16. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Oda N; Imamura S; Fujita T; Uchida Y; Inagaki K; Kakizawa H; Hayakawa N; Suzuki A; Takeda J; Horikawa Y; Itoh M
Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
[TBL] [Abstract][Full Text] [Related]
17. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
Fritsche A; Schmülling RM; Häring HU; Stumvoll M
Acta Diabetol; 2000 Mar; 37(1):13-8. PubMed ID: 10928231
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
19. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
